Guarantor Information (Condensed Consolidating Statements of Cash Flows) (Details) - USD ($) $ in Thousands	5 Months Ended	7 Months Ended	12 Months Ended
	Dec. 31, 2015	Aug. 14, 2015	Dec. 31, 2016	Dec. 31, 2014
Successor [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash (used in) provided by operating activities	$ 23,115		$ 22,815
Cash flow from investing activities:
(Loans to) repayments from affiliates	0
Capital expenditures	(18,442)		(27,858)
Insurance proceeds	0		0
Derivative instrument settlements, net	326		377
Proceeds from the sale of fixed assets	632		1,121
Cash received from divestitures	0		15,889
Other	0		0
Net cash used in investing activities	(17,484)		(10,471)
Loans from (repayments to) affiliates	0
Short-term debt borrowings	(15,504)		7,363
Credit Facility borrowings	62,000		56,000
Revolving Facility reductions	(68,000)		(70,469)
Repayment of Senior Subordinated Notes	0		0
Issuance of preferred shares	(1,385)
Principal payments on long term debt	(183)		(289)
Supply chain financing	0		0
Proceeds from exercise of stock options	0		0
Purchase of treasury shares	0		0
Refinancing fees and debt issuance costs	0		(922)
Other	(1,385)		0
Net cash (used in) provided by financing activities	(23,072)		(8,317)
Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect	(17,441)		4,027
Effect of exchange rate changes on cash and cash equivalents	(665)		656
Cash and cash equivalents at beginning of period	25,033		6,927
Cash and cash equivalents at end of period	6,927	$ 25,033	11,610
Successor [Member] | Consolidating Entries and Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash (used in) provided by operating activities	0
Cash flow from investing activities:
(Loans to) repayments from affiliates	17,315
Capital expenditures	0
Derivative instrument settlements, net	0
Proceeds from the sale of fixed assets	0
Net cash used in investing activities	17,315
Loans from (repayments to) affiliates	(17,315)
Short-term debt borrowings	0
Credit Facility borrowings	0
Revolving Facility reductions	0
Issuance of preferred shares	0
Principal payments on long term debt	0
Net cash (used in) provided by financing activities	(17,315)
Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect	0
Effect of exchange rate changes on cash and cash equivalents	0
Cash and cash equivalents at beginning of period	0		0
Cash and cash equivalents at end of period	0	0	0
Successor [Member] | Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash (used in) provided by operating activities	(15,930)
Cash flow from investing activities:
(Loans to) repayments from affiliates	0
Capital expenditures	0
Derivative instrument settlements, net	0
Proceeds from the sale of fixed assets	0
Net cash used in investing activities	0
Loans from (repayments to) affiliates	17,315
Short-term debt borrowings	0
Credit Facility borrowings	0
Revolving Facility reductions	0
Issuance of preferred shares	(1,385)
Principal payments on long term debt	0
Net cash (used in) provided by financing activities	15,930
Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect	0
Effect of exchange rate changes on cash and cash equivalents	0
Cash and cash equivalents at beginning of period	0		0
Cash and cash equivalents at end of period	0	0	0
Successor [Member] | Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash (used in) provided by operating activities	18,471
Cash flow from investing activities:
(Loans to) repayments from affiliates	(17,315)
Capital expenditures	(8,438)
Derivative instrument settlements, net	0
Proceeds from the sale of fixed assets	492
Net cash used in investing activities	(25,261)
Loans from (repayments to) affiliates	0
Short-term debt borrowings	(10,998)
Credit Facility borrowings	52,000
Revolving Facility reductions	(36,000)
Issuance of preferred shares	0
Principal payments on long term debt	(46)
Net cash (used in) provided by financing activities	4,956
Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect	(1,834)
Effect of exchange rate changes on cash and cash equivalents	0
Cash and cash equivalents at beginning of period	2,480		646
Cash and cash equivalents at end of period	646	2,480	636
Successor [Member] | Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash (used in) provided by operating activities	20,574
Cash flow from investing activities:
(Loans to) repayments from affiliates	0
Capital expenditures	(10,004)
Derivative instrument settlements, net	326
Proceeds from the sale of fixed assets	140
Net cash used in investing activities	(9,538)
Loans from (repayments to) affiliates	0
Short-term debt borrowings	(4,506)
Credit Facility borrowings	10,000
Revolving Facility reductions	(32,000)
Issuance of preferred shares	0
Principal payments on long term debt	(137)
Net cash (used in) provided by financing activities	(26,643)
Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect	(15,607)
Effect of exchange rate changes on cash and cash equivalents	(665)
Cash and cash equivalents at beginning of period	22,553		6,281
Cash and cash equivalents at end of period	6,281	22,553	10,974
Predecessor [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash (used in) provided by operating activities		28,323	22,815	$ 120,903
Cash flow from investing activities:
(Loans to) repayments from affiliates		0	0	0
Capital expenditures		(32,301)	(27,858)	(84,981)
Insurance proceeds		0		2,834
Derivative instrument settlements, net		(8,263)	377	(2,025)
Proceeds from the sale of fixed assets		646	1,121	5,042
Cash received from divestitures		0	15,889	0
Other		0		178
Net cash used in investing activities		(39,918)	(10,471)	(78,952)
Loans from (repayments to) affiliates		0	0	0
Short-term debt borrowings		18,511	7,363	(1,021)
Credit Facility borrowings		160,000	56,000	269,000
Revolving Facility reductions		(99,000)	(70,469)	(293,000)
Repayment of Senior Subordinated Notes		(200,000)		0
Issuance of preferred shares	0	(150,000)	0	0
Principal payments on long term debt		(89)	(289)	(192)
Supply chain financing		0		(9,455)
Proceeds from exercise of stock options		32		2,813
Purchase of treasury shares		(63)		(894)
Refinancing fees and debt issuance costs		(5,068)	(922)	(3,279)
Other		(3,499)		951
Net cash (used in) provided by financing activities		20,824	(8,317)	(35,077)
Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect		9,229	4,027	6,874
Effect of exchange rate changes on cash and cash equivalents		(1,746)	656	(1,212)
Cash and cash equivalents at beginning of period	25,033	17,550	6,927	11,888
Cash and cash equivalents at end of period	6,927	25,033	11,610	17,550
Predecessor [Member] | Consolidating Entries and Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash (used in) provided by operating activities		(27,710)	0	0
Cash flow from investing activities:
(Loans to) repayments from affiliates		(14,861)	2,067	(6,604)
Capital expenditures		0	0	0
Insurance proceeds				0
Derivative instrument settlements, net		0	0	0
Proceeds from the sale of fixed assets		0	0	0
Cash received from divestitures			0
Other				0
Net cash used in investing activities		(14,861)	2,067	(6,604)
Loans from (repayments to) affiliates		14,861	(2,067)	6,604
Dividends to affiliates		27,710
Short-term debt borrowings		0	0	0
Credit Facility borrowings		0	0	0
Revolving Facility reductions		0	0	0
Repayment of Senior Subordinated Notes		0
Issuance of preferred shares		0
Principal payments on long term debt		0	0	0
Supply chain financing				0
Proceeds from exercise of stock options		0		0
Purchase of treasury shares		0		0
Refinancing fees and debt issuance costs		0	0	0
Other		0		0
Net cash (used in) provided by financing activities		42,571	(2,067)	6,604
Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect		0	0	0
Effect of exchange rate changes on cash and cash equivalents		0	0	0
Cash and cash equivalents at beginning of period	0	0	0	0
Cash and cash equivalents at end of period	0	0	0	0
Predecessor [Member] | Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash (used in) provided by operating activities		(4,017)	(19,032)	(9,474)
Cash flow from investing activities:
(Loans to) repayments from affiliates		36,204	0	6,604
Capital expenditures		0	0	0
Insurance proceeds				0
Derivative instrument settlements, net		0	0	0
Proceeds from the sale of fixed assets		0	0	0
Cash received from divestitures			16,173
Other				0
Net cash used in investing activities		36,204	16,173	6,604
Loans from (repayments to) affiliates		21,343	2,067	0
Dividends to affiliates		0
Short-term debt borrowings		0	0	0
Credit Facility borrowings		0	0	0
Revolving Facility reductions		0	0	0
Repayment of Senior Subordinated Notes		(200,000)
Issuance of preferred shares		(150,000)
Principal payments on long term debt		0	0	0
Supply chain financing				0
Proceeds from exercise of stock options		32		2,813
Purchase of treasury shares		(63)		(894)
Refinancing fees and debt issuance costs		0	0	0
Other		(3,499)		951
Net cash (used in) provided by financing activities		(32,187)	2,859	2,870
Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect		0	0	0
Effect of exchange rate changes on cash and cash equivalents		0	0	0
Cash and cash equivalents at beginning of period	0	0	0	0
Cash and cash equivalents at end of period	0	0	0	0
Predecessor [Member] | Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash (used in) provided by operating activities		34,418	25,527	79,864
Cash flow from investing activities:
(Loans to) repayments from affiliates		(21,343)	(2,067)	0
Capital expenditures		(20,572)	(9,019)	(58,926)
Insurance proceeds				0
Derivative instrument settlements, net		(7,595)	0	(2,195)
Proceeds from the sale of fixed assets		397	462	1,700
Cash received from divestitures			(284)
Other				0
Net cash used in investing activities		(49,113)	(10,908)	(59,421)
Loans from (repayments to) affiliates		(36,204)	0	(6,604)
Dividends to affiliates		0
Short-term debt borrowings		14,002	1,705	(34)
Credit Facility borrowings		126,000	51,000	183,000
Revolving Facility reductions		(87,000)	(65,469)	(193,000)
Repayment of Senior Subordinated Notes		0
Issuance of preferred shares		0
Principal payments on long term debt		(89)	(151)	(132)
Supply chain financing				0
Proceeds from exercise of stock options		0		0
Purchase of treasury shares		0		0
Refinancing fees and debt issuance costs		(5,037)	(922)	(2,922)
Other		0		0
Net cash (used in) provided by financing activities		11,672	(14,629)	(19,692)
Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect		(3,023)	(10)	751
Effect of exchange rate changes on cash and cash equivalents		0	0	0
Cash and cash equivalents at beginning of period	2,480	5,503	646	4,752
Cash and cash equivalents at end of period	646	2,480	636	5,503
Predecessor [Member] | Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash (used in) provided by operating activities		25,632	16,320	50,513
Cash flow from investing activities:
(Loans to) repayments from affiliates		0	0	0
Capital expenditures		(11,729)	(18,839)	(26,055)
Insurance proceeds				2,834
Derivative instrument settlements, net		(668)	377	170
Proceeds from the sale of fixed assets		249	659	3,342
Cash received from divestitures			0
Other				178
Net cash used in investing activities		(12,148)	(17,803)	(19,531)
Loans from (repayments to) affiliates		0	0	0
Dividends to affiliates		(27,710)
Short-term debt borrowings		4,509	5,658	(987)
Credit Facility borrowings		34,000	5,000	86,000
Revolving Facility reductions		(12,000)	(5,000)	(100,000)
Repayment of Senior Subordinated Notes		0
Issuance of preferred shares		0
Principal payments on long term debt		0	(138)	(60)
Supply chain financing				(9,455)
Proceeds from exercise of stock options		0		0
Purchase of treasury shares		0		0
Refinancing fees and debt issuance costs		(31)	0	(357)
Other		0		0
Net cash (used in) provided by financing activities		(1,232)	5,520	(24,859)
Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect		12,252	4,037	6,123
Effect of exchange rate changes on cash and cash equivalents		(1,746)	656	(1,212)
Cash and cash equivalents at beginning of period	22,553	12,047	6,281	7,136
Cash and cash equivalents at end of period	$ 6,281	$ 22,553	$ 10,974	$ 12,047